Pursuant to Executive Order (EO) 13944 Executive Order on Ensuring Essential Medicines, Medical Countermeasures, and Critical Inputs Are Made in the United States and implementing DOGE EO 14222 efforts to reduce duplicative efforts and maximize cost effectiveness, this briefing will provide an overview and current manufacturing capacity of US made COVID-19/Influenza A&B combination tests for agencies who require testing solutions.

Session Objectives:

• Provide Awareness of US Made testing supply chain
• Help federal agencies plan for and meet demand for 2025/26 Covid & Flu Season
• Review cost savings and point of care efficiencies of using combined tests
• Review manufacture direct cost vs distribution
• Review procurement methods for purchasing manufacture direct

This session will include review of industry provided commercial off the shelf (COTS) products provided by WELLlife™. Verified agency attendees may request samples of WELLlife™ COVID-19/Influenza A&B test kits. Additional information will be provided regarding how WELLlife™ tests can differentiate between SARS-COV-2, influenza A and influenza B antigens with a single test.

Agency Panelist Participation

Agency participation is encouraged for this briefing. If you or one of your colleagues would like to be a contributor or panelist in this discussion, please contact support@govbrief.us or call 888-818-8726 to coordinate your participation. GovBrief provides free access to all government presenters and will distribute all accompanying documentation at no charge.

Recommended attending personnel:

Medical supply managers, DOGE team leads and support personnel, medical administrators, procurement professionals responsible for medical supplies, medical practitioners, nurses and other medical providers.

Important: This briefing uses a Zoom-based communication connection via your network. This briefing will be accessible via phone if you are unable to connect online and recorded versions will be distributed with closed-caption for the hearing impaired. Instructions for login will be provided upon registration.

Topical Overview

Federal Initiatives

Current Manufacturing Capacity

Meeting Demand for 2025/26 Flu Season

• Efficiency
• Cost Savings

The Use of Combined Tests

• Collection Protocol
• Trained Staff
• Increased Productivity
• Manufacture direct cost vs distribution

Next Steps

• Continuing the Conversation
• Procurement Options

Closing Remarks